Adam JacksonOctober 24, 2022
Canadian clinical stage drug development company, Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF), has entered a clinical trial agreement with Yale University to study DMT for the treatment of depression. Algernon will provide DMT for the study in return for intellectual property rights with Yale around the clinical use of the drug. The company will […]
